Zanzalintinib (XL092)

Name: Zanzalintinib (XL092) in Metastatic colorectal cancer: Economic impact of Metastatic colorectal cancer on families
Published: 2026-09-14T15:39:06-04:00

Metastatic colorectal cancer

Manufacturer: Exelixis
Regulatory submission: NDA submitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Metastatic colorectal cancer

Economic impact of Metastatic colorectal cancer on families

1 evidence topic · 1 source

Patient-reported household financial hardship at 12 months

Financial hardship component	Cumulative incidence
Income decline of at least 20%	“26.6%”
Loans from family or friends	“26.0%”